14.02.2019 • NewsAbbVieElaine Burridge

AbbVie and Teneobio Link on Multiple Myeloma

AbbVie and Teneobio Link on Multiple Myeloma (c) Teneobio
AbbVie and Teneobio Link on Multiple Myeloma (c) Teneobio

US biopharma AbbVie has agreed a deal with Teneobio, a California-based biotech, to develop and commercialize an immunotherapeutic that targets B-cell maturation antigen (BCMA) for treating multiple myeloma, a type of blood cancer.

Under the terms of the transaction, AbbVie will pay $90 million upfront to develop Teneobio’s TNB-383B, a bispecific antibody.

AbbVie said BCMA has emerged as an attractive target for multiple myeloma therapeutics. TNB-383B simultaneously targets BCMA and the CD3 antigen, using Teneobio’s unique anti-CD3 platform. Through the dual targeting mechanism, TNB-383B is designed to direct the body’s own immune system to target and kill BCMA expressing tumor cells.

“Developing novel targeted treatments for patients with cancer continues to be our key priority,” said Mohit Trikha, vice president and head, oncology early development at AbbVie. “Multiple myeloma is one of the most common hematological cancers and an area of significant medical need. Teneobio’s novel approach to T-cell redirection with TNB-383B has the potential to be a treatment option that may offer new hope for myeloma patients.”

Teneobio is expected to begin the clinical program for TNB-383B in the first half of 2019.

Special Issue

Circular Plastics Economy
Explore the Future of Plastics

Circular Plastics Economy

This special CHEManager issue explores the industry’s pivotal shift towards a more sustainable, circular plastics value chain. Readers will find expert analysis and real-world solutions for today’s most pressing recycling and regulatory challenges.

Free Expert Insights

Dual‑Targeting Breakthroughs
Advancements in Bispecific Antibody Development

Dual‑Targeting Breakthroughs

Unlock the latest breakthroughs in bispecific antibody development! Download Wiley’s free Expert Insights eBook to explore cutting-edge dual-targeting strategies, advanced purification methods, and bioanalytical technologies transforming immunotherapy and cancer treatment.

most read

Photo
28.07.2025 • NewsChemistry

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.